Drugs / DSP-0390
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06636162 | Apr 2025 → Apr 2027 expected | malignant glioma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 0 | NCT05023551 | Sep 2021 → Sep 2026 overdue | glioblastoma | Sumitomo Pharma America, Inc. | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07545954 | Jul 2026 → Aug 2029 expected | small cell lung carcinoma | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSP-0390 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05023551 ↗ |
| Action | Inhibit | “inhibition of de novo cholesterol synthesis by DSP-0390” NCT07545954 ↗ |
| Modality | Small molecule | — CHEMBL5314914 ↗ |
| Route | Oral | “administered orally” NCT05023551 ↗ |
| Target | EBP | “EBP inhibitor DSP-0390” NCT07545954 ↗ |